Average infused TNC/kg Â 10 7 was 2.9 (1.9-5.8) and 4.7 (0.6-9.1) for the non-cultured and cultured cells respectively, and infused CD34 cells/kg (Â10 5 ) was 2.2 (1.1-3.4) and 55 (9.1-136) respectively. No toxicities directly attributable to the cultured product, including infusional, increased acute GVHD, or graft failure have been observed. Relatively rapid engraftment was observed in 7 of 8 patients with a median time to engraftment of 16 days (7 to 34), as compared to 25 days (16 to 48) in patients (n 5 17) undergoing an identical transplant regimen here, but with 2 noncultured CBU. Relative contribution of the expanded and non-cultured grafts over time was determined by a DNA-based assay on peripheral blood, beginning day 7 post transplant. Engrafted myeloid cells present at day 7 were derived almost entirely from the expanded unit in 7 patients. In 3 of 7, ANC . 500 was observed at days 7, 9 and 16 and was mainly derived from the expanded unit, whereas in the other 4 patients who achieved ANC . 500 at day 13, 16, 20 and 21, myeloid engraftment at day 14 was derived from the non-cultured cells. Persistent engraftment from the expanded cells has been noted in 2 patients, one through 280 days post transplant and one who is currently 125 days post transplant in whom the expanded cells continue to dominate in CD33, CD14 and CD56 sorted cell fractions. Average follow-up time is 287 days (range 56-680). One patient died on day 462 from complications of VZV myelitis; all other patients are alive and in remission. Thus, improvement in early myeloid reconstitution may result from provision of short term repopulating cells and/or of cells able to facilitate engraftment of the non-cultured unit. These studies continue with the goal of achieving consistent, rapid engraftment in recipients of hematopoietic cell transplants to decrease morbidity and mortality in the early post-transplant setting.
GVH/GVL 25 TARGETED PROTECTION OF THE COLON IN THE ABSENCE OF DONOR ANTIGEN-PRESENTING CELL -DERIVED INTERLEUKIN 23 ALLOWS FOR SEPARATION OF GRAFT VERSUS HOST AND GRAFT VERSUS LEUKEMIA EFFECTS
Das, R., Drobyski, W.R. Medical College of Wisconsin, Milwaukee, WI Separation of graft versus leukemia (GVL) and graft versus host (GVH) reactivity has been a longstanding but elusive goal in allogeneic bone marrow transplantation (BMT). Recent studies from our laboratory have shown that donor APC-derived IL-23 secretion has a critical role in mediating pathological damage in the colon during GVHD, but has no protective effect in other GVHD target organs such as the lung and liver. These results demonstrate the feasibility of regional GVHD protection and raise the question as to whether such localized protection might be a strategy to separate GVH and GVL responses. To directly address this question, we employed a novel, clinically relevant murine model of chronic myelogenous leukemia (CML). In this model, FVB animals that have the bcr/abl oncogene under the control of a tetracycline-inducible repressor are used as donor animals (i.e. CML mice). Lethally irradiated normal FVB mice were transplanted with equivalent numbers (10 7 ) of T cell depleted BM from B6 and FVB CML animals. Withdrawal of tetracycline from the drinking water induces expression of the bcr/abl oncogene and the development of granulocytic hyperplasia and splenomegaly in transplanted mice. Additional cohorts of animals were also transplanted with the same BM inoculum plus 3.5 Â 10 6 T cells from either wild type or IL-23 -/-donors to determine if GVL and GVH effects could be dissociated. Whereas mice that received adjunctive B6 T cells succumbed from fatal GVHD, animals transplanted with T cells from IL-23 -/-mice had significantly prolonged survival and no evidence of leukemia by blood counts or pathological examination. In order to address the role of IL-23 in the GVL response directed against leukemia with more aggressive kinetics, similar studies were performed using a Balbderived A20 leukemia cell line. Transplantation with BM and spleen cells from IL-23 -/-donor mice resulted in significantly prolonged survival when compared to mice reconstituted with similarly composed marrow grafts from wild type B6 animals. A five-fold escalation of the A20 cell dose produced similar protective results in recipients of IL-23 -/-marrow grafts. In conclusion, these studies show that in the absence of donor APC-derived IL- Background: Graft-vs-host disease (GvHD) and lyphopenia are the major clinical problems in allogeneic bone marrow transplantation (BMT). Immunosuppressive drugs are used to control GvHD, but immunosuppression is often incomplete and patients experience drug-related toxicities. Donor foxp31CD251CD41 regulatory T cells are also effective at controlling GvHD, but are expensive and time consuming to produce. Flagellin, a bacterial protein and a TLR5 agonist, can culminate production of proinflammatory cytokines and chemokines. In this study we investigated whether flagellin could facilitate thymic production of donor BM-derived foxp31CD251CD41 regulatory T cells to control GvHD and regulate post BMT immune reconstitution.
Methods: Irradiated (11Gy) CB6F1 recipient received 5 Â 10 6 T cell depleted BM and 5 Â 10 6 splenocytes from naive C57BL/6 congenic donors. 50 micro gm flagellin/mouse was administered i.p. 3 hours before irradiation and 24 hours after BMT. Recipients that received no flagellin were used as control. After 701 days post transplant recipients were infected with 5 Â 10 3 pfu MCMV i.p., sacrificed at different time points and lymphocytes were harvested from spleen and thymus for analysis. Flow cytometry was used to determine immune reconstitution, normal and regulatory T cells.
Results: All flagellin-treated recipients survived without GvHD for 66 days post transplant, while only 65% of the control mice survived and had chronic GvHD. The number of splenocytes was significantly increased in flagellin-treated recipients compared to control recipients (p 5 0.0006) on day 66-post transplant. Donor spleen-and BM-derived CD41 and CD81 T cells were significantly higher in the spleen of flagellin-treated recipients compared to control mice. Flagellin-treated recipients had higher levels of both donor spleen-and BM-derived anti-viral CD81 T cells in the spleen compared to control recipients. The thymus of flagellin-treated recipients produced donor spleen-and BM-derived T cells and foxp31CD251CD41 regulatory T cells, while thymic functions were severely reduced in control recipients.
Conclusion: Flagellin treatment successfully reduced GvHD, improved survival, enhanced donor T-cell engraftment and produced regulatory T cells in allo-BMT. Treated recipients had brisk and persistent cellular immune responses against MCMV infection. Hence, prophylactic use of flagellin is a novel therapeutic approach to treat blood cancer patients with allogeneic BMT. 3 National Institute of Health, Bethesda, MD A higher lymphocyte count one month after allogeneic stem cell transplantation (SCT) is associated with better outcome in patients transplanted from an HLA-identical sibling. However, a predictive role of the day 30 post-transplant absolute lymphocyte count (LC30) in unrelated transplants is not defined. We studied the relationship between LC30 and outcome in 102 patients with myeloid leukemia receiving myeloablative SCT from matched unrelated donors. Conditioning consisted of cyclophosphamide with Busulphan (n 5 61) or total body irradiation (n 5 41). Immunosuppression was cyclosporine with four doses of methotrexate in 97 patients and other treatments in 5. Overall survival at 5 years was 61% and relapse-free survival was 56%. The incidence of acute GvHD grades II-IV was 62% in patients with an LC30 of \0.2 Â 10 9 /L, 33% if the LC30 was 0.2-1.0 Â 10 9 /L and 25% in patients with an LC30 .1.0 Â 10 9 /L (p 5 0.008). Transplant related mortality (TRM) was 34% in patients with an LC30 \0.2 Â 10 9 versus 19% (LC30 of 0.2-1.0 Â 10 9 ) and 0% (LC30 .1.0 Â 10 9 ) (p\0.001). Survival was significantly higher in 17 patients with an LC30 .1.0 Â 10 9 /L, compared to 67 patients with an LC30 0.2-1.0 Â 10 9 /L, and 18 patients with \0.2 Â 10 9 /L (91% vs. 60%, vs. 36% p 5 0.02 and 0.001 respectively). When analyzed as a continuous variable in multivariate analysis, a higher LC30 was associated with a lower incidence of acute GvHD grades II-IV, improved survival, less relapse and higher relapse-free survival. Plasma levels of cytokines were measured in 15 subjects between day 12-32 post-transplant (total 21 samples). Six patients had a low (\0.2 Â10 9 /L) and 9 patients a high (.1.0 Â 10 9 /L) LC30. Plasma IL-15 was lower in patients with high LC30 (median 32 pg/ml vs. 56.5 pg/ml, p \0.05 log rank sum). These results indicate that the LC30 is a robust prognostic factor for transplant outcome in matched unrelated as well as matched related SCT for myeloid malignancies receiving either BM or PBSC with or without irradiation conditioning. Further research to identify the transplant conditions leading to prompt lymphocyte recovery might lead to global improvements in SCT outcome in unrelated SCT. 6 T-cell depleted bone marrow (TCD-BM) from wild-type (WT) C57BL/6 mice, and monitored them by bioluminescence imaging (BLI). By day 4 after transfer, a signal was observed in spleen and lymph node (LN) sites, and between days 7 and 10, NKT had also migrated to skin. Total photons emitted peaked around day 25 after transplantation, followed by a steady decline. To assess the impact of donor-type NKT on GVHD induction by Tcon, we co-transferred various doses of highly pure WT NKT at day 0 with 5 Â 10 6 TCD-BM, followed by 5 Â 10 5 luc1Tcon at day 2. We have found that adoptive transfer of as few as 2.5 Â 10 4 NKT can significantly improve survival of mice receiving 5 Â 10 5 Tcon. Survival with Tcon only was 20% and for Tcon with NKT was 74%; p 5 0.0023. To determine how NKT reduce GVHD, we examined intracellular levels of various cytokines in Tcon with or without 2.5 Â 10 4 NKT, following HCT. At 8 days after HCT, mice receiving NKT had fewer TNFa-positive cells from LNs (CD4: 45% to 27%; CD8 36% to 24%); by day 11, however, TNFa levels between groups were equivalent. IFN-g levels, which were high in both NKT treated and untreated groups at day 8 (85%-95%), decreased significantly in NKT treated mice by day 11 (CD4: 40%; CD8: 43%), but were abundant in Tcon only mice (CD4: 78%; CD8: 80%) (p 5 .0001). NKT from both IL-4 -/-and IFN-g -/-mice were less effective at suppressing GVHD than WT NKT, implicating these cytokines in the suppressive mechanism. Finally, we found that NKT do not have a major impact on the graft-versus-tumor effect of Tcon against a luc1BCL-1 tumor. These studies indicate that NKT persist in vivo upon adoptive transfer and suppress GVHD, even at extremely low cell numbers, which is important given the relative paucity of this cell population. The mechanisms of GVHD suppression appear to be distinct to those of CD41CD251FoxP31 Treg and involve the production of IL-4 and IFN-g by NKT and a decrease in Tcon which produce pro-inflamatory cytokines.
LYMPHOCYTE RECOVERY IS A MAJOR DETERMINANT OF TRANSPLANT OUTCOME AFTER MYELOABLATIVE TRANSPLANTATION IN PATIENTS WITH MYELOID MALIGNANCIES RECEIVING MATCHED UNRELATED STEM CELL ALLOGRAFTS
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